Terms: = Breast cancer AND MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7 AND Treatment
438 results:
1. Decoding the Versatile Landscape of Autophagic Protein VMP1 in cancer: A Comprehensive Review across Tissue Types and Regulatory Mechanisms.
Renna FJ; Gonzalez CD; Vaccaro MI
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612567
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer.
Li Y; Li G; Zuo C; Wang X; Han F; Jia Y; Shang H; Tian Y
Eur J Med Chem; 2024 Apr; 270():116367. PubMed ID: 38581732
[TBL] [Abstract] [Full Text] [Related]
3. Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative breast cancer Treated with Neoadjuvant Therapy.
Arqueros C; Gallardo A; Vidal S; Osuna-Gómez R; Tibau A; Lidia Bell O; Ramón Y Cajal T; Lerma E; Lobato-Delgado B; Salazar J; Barnadas A
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473874
[TBL] [Abstract] [Full Text] [Related]
4. Telocinobufagin, a PLK1 suppressor that inhibits tumor growth and metastasis by modulating CDC25c and CTCF in HNSCC cells.
Li J; Ma R; Lv JL; Ren YS; Tan YJ; Wang HM; Wang ZE; Wang BS; Yu JN; Wang YL; Tian J; Zheng QS
Phytomedicine; 2024 May; 127():155440. PubMed ID: 38452691
[TBL] [Abstract] [Full Text] [Related]
5. Long-term outcomes with HLX01 (HanliKang
Qin Y; Song Y; Wang D; Bai O; Feng J; Sun X; Qiu L; Yang J; Yang Y; Wang Z; Hu J; Wang H; Su H; Jin Z; Qian W; Jin C; Zhang M; Yu D; Liu L; Chen G; Li Y; Sun T; Jin J; Bao H; Du X; Zhou H; Fu G; Shi Y
BMC Cancer; 2024 Jan; 24(1):124. PubMed ID: 38267866
[TBL] [Abstract] [Full Text] [Related]
6. Therapy-induced senescent cancer cells exhibit complement activation and increased complement regulatory protein expression.
Abu-Humaidan AH; Ismail MA; Ahmad FM; Al Shboul S; Barham R; Tadros JS; Alhesa A; El-Sadoni M; Alotaibi MR; Ababneh NA; Saleh T
Immunol Cell Biol; 2024 Apr; 102(4):240-255. PubMed ID: 38265162
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Fasching PA; Decker T; Hartkopf A; Nusch A; Heinrich BJ; Kurbacher C; Fuchs R; Tesch H; Krabisch P; Huober J; Kuemmel S; Brucker S; Janni W; Schneeweiss A; Schuler M; Fehm T; Lüftner D; Quiering C; Voges C; Kreuzeder J; Reinisch M
Eur J Cancer; 2024 Feb; 198():113480. PubMed ID: 38154393
[TBL] [Abstract] [Full Text] [Related]
8. Inhibition of Drp1 orchestrates the responsiveness of breast cancer cells to paclitaxel but insignificantly relieves paclitaxel-related ovarian damage in mice.
Alalawy AI; Sakran M; Alzuaibr FM; Alotaibi MA; El-Hefnawy ME; Hazazi AY; El-Gendy SM; Aidy EA; Effat H; Ismail DF; Hessien M
Sci Rep; 2023 Dec; 13(1):22782. PubMed ID: 38129495
[TBL] [Abstract] [Full Text] [Related]
9. Therapeutic Efficacy of Oxaliplatin and Pembrolizumab Combination treatment for Triple-Negative breast cancer.
Chu SL
Stud Health Technol Inform; 2023 Nov; 308():341-350. PubMed ID: 38007758
[TBL] [Abstract] [Full Text] [Related]
10. Hot-Spot Residue-Based Virtual Screening of Novel Selective Estrogen-Receptor Degraders for breast cancer treatment.
Dai R; Bao X; Zhang Y; Huang Y; Zhu H; Yang K; Wang B; Wen H; Li W; Liu J
J Chem Inf Model; 2023 Dec; 63(23):7588-7602. PubMed ID: 37994801
[TBL] [Abstract] [Full Text] [Related]
11. Repurposing of Strychnine as the Potential Inhibitors of Aldo-keto Reductase Family 1 Members B1 and B10: Computational Modeling and Pharmacokinetic Analysis.
Sarfraz M; Aziz M; Afzal S; Channar PA; Alsfouk BA; Kandhro GA; Hassan S; Sultan A; Hamad A; Arafat M; Qaiser MN; Ahmed A; Siddique F; Ejaz SA
Protein J; 2024 Apr; 43(2):207-224. PubMed ID: 37940790
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
13. Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review.
Huang F; Ruan Y; He X; Lian H; Yang J
World J Surg Oncol; 2023 Oct; 21(1):342. PubMed ID: 37884941
[TBL] [Abstract] [Full Text] [Related]
14. Cullin-associated and neddylation-dissociated 1 regulate reprogramming of lipid metabolism through SKP1-Cullin-1-F-box
Zhang H; Xia P; Yang Z; Liu J; Zhu Y; Huang Z; Zhang Z; Yuan Y
Clin Transl Med; 2023 Oct; 13(10):e1443. PubMed ID: 37837399
[TBL] [Abstract] [Full Text] [Related]
15. [Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day].
Ranchon F; Chatelut É; Lambert J; Sesques P; Thibault C; Madelaine I; Rioufol C; Diéras V; Cazin JL
Bull Cancer; 2023 Dec; 110(12):1343-1351. PubMed ID: 37827964
[TBL] [Abstract] [Full Text] [Related]
16. TRPV4 Activation and its Intracellular Modulation Mediated by Kinin Receptors Contribute to Painful Symptoms Induced by Anastrozole.
Fialho MFP; Brum ES; Becker G; Oliveira SM
Mol Neurobiol; 2024 Mar; 61(3):1627-1642. PubMed ID: 37740866
[TBL] [Abstract] [Full Text] [Related]
17. Pseudolaric acid B induces apoptosis associated with the mitochondrial and PI3K/AKT/mTOR pathways in triple‑negative breast cancer.
Yang K; Wang JQ; Li K; Chen SN; Yu F
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37711030
[TBL] [Abstract] [Full Text] [Related]
18. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal cancer and Invasive breast cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract] [Full Text] [Related]
19. CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases.
Petruk N; Siddiqui A; Tadayon S; Määttä J; Mattila PK; Jukkola A; Sandholm J; Selander KS
Front Immunol; 2023; 14():1179022. PubMed ID: 37533856
[TBL] [Abstract] [Full Text] [Related]
20. Dependency of Tamoxifen Sensitive and Resistant ER
Bhasin S; Dusek C; Peacock JW; Cherkasov A; Wang Y; Gleave M; Ong CJ
Cells; 2023 Jun; 12(13):. PubMed ID: 37443749
[TBL] [Abstract] [Full Text] [Related]
[Next]
